BINV — BioInvent International AB Share News
0.000.00%
Last trade - 00:00- SEK1.33bn
- SEK1.01bn
- SEK226.50m
Brief: BioInvent Q1 Sales SEK 22.1 Million
Brief: Bioinvent Receives FDA Orphan Drug Designation For Bi-1808
Brief: BioInvent Q4 Sales SEK 21.4 Million
Brief: Bioinvent: Promising Initial Efficacy Data From Triple Combination Arm Of BI-1206, Rituximab And Calquence
Brief: Bioinvent Announces Data From Phase 1 Study In Solid Tumors
Brief: BioInvent Q3 Sales SEK 12.8 Million
Brief: Bioinvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity
Brief: BioInvent Q2 Sales SEK 4.6 Million
Brief: Bioinvent To Present Pipeline Progress On Bi-1910 And Bt-001 At Esmo
Brief: Bioinvent Announces New Clinical Trial Collaboration
Brief: Bioinvent Gets Patent For Bi-1808 In China
Brief: BioInvent Q1 Sales SEK 5.9 Million
Brief: Bioinvent Announces Clinical Trial Collaboration, Supply Agreement With MSD
Brief: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206
Brief: BioInvent Q4 Sales SEK 15.3 Million
Brief: Bioinvent Regains Rights To Immuno-Oncology Targets From Exelixis
Brief: Bioinvent Says Is Well-Funded With SEK 1,358 Mln
Brief: BioInvent Presents Positive First Clinical Data On Anti-FcyRIIB Antibody BI-1607
Brief: Bioinvent Presents Data Providing Evidence Of The Potential Of Anti-Tnfr2 Antibody Bi-1910